Issue: Controlled-release technologies are being adapted in psychopharmacology at an increasing rate and can enhance the utility of numerous psychiatric drugs.
AT LONG LAST, LONG LASTING
Technologies that can change the delivery characteristics of drugs have been around for decades, 1 but there has been a recent acceleration in the pace of their adaptation to psychiatric medications (Tables 1-3 ). Most notable is the increasing availability of numerous agents in oral sustained-release formulations that increase a drug's duration of action. By allowing the frequency of dosing to be reduced from 2 or 3 times a day to once a day, compliance can be greatly enhanced. 2 This development has proved to be particularly important for school-aged children receiving stimulants, since controlled-release technology now allows them to skip the hassle and stigma of receiving a middle-of-theday dose at school (see Table 2 ).
I'VE GOT YOU UNDER MY SKIN
New to psychopharmacology are some drugs that can be delivered through the skin via transdermal patches; these include both an antidepressant (Table 1 ) and a stimulant (Table 2) being tested in a once-daily transdermal patch. Since transdermal administration avoids first-pass metabolism of the drug, the amounts of parent drug and active metabolites of transdermally administered drug are altered compared with orally administered drug. This feature may result in a more favorable side effect and efficacy outcome in some cases. 3 It may soon be possible to administer atypical antipsychotics in longlasting injectable forms. One version on the immediate horizon is a longacting injectable form of risperidone that was developed by utilizing drug encapsulated in microspheres made of a biodegradable polymer that are suspended in a water-based solution and administered to patients by intramuscular injection and can last for 2 weeks. 4 This long-awaited development could greatly enhance compliance and reduce various high-cost prescribing practices, such as polypharmacy and high dosing, for patients with psychosis.
NO MORE ROLLER COASTER DRUG DELIVERY
A sawtooth pattern of rapid rises and falls in plasma drug levels can wreak havoc by causing side effects at the peak and loss of therapeutic effects at the trough. Sometimes it's the rate of rise and fall rather than the absolute level of drug that matters the most in causing side effects. It is now generally acknowledged that oral sustained-release delivery technologies have enhanced the tolerability of numerous psychotropic drugs, sometimes dramatically (Tables 2 and 3) . Thus, adverse experiences associated with high peak doses, ranging from seizures to alopecia to nausea to sedation, are now widely recognized to be mitigated or even eliminated by applying controlled-release technologies to specific psychotropic drugs that cause the agents to be delivered in a manner that results in a more constant plasma level. Lowering the peaks and raising the troughs while slowing the rate of ascent and descent of drug can smooth out the roller coaster ride of drug delivery and result in important patient benefits.
IT'S ABOUT TIME FOR TIME RELEASE
In summary, new drug delivery technologies are helping to optimize the efficacy and tolerability of numerous psychotropic drugs, which should lead to greater compliance while reducing side effects. Given that many psychotropic drugs have delays in onset of action for the treatment of acute symptoms while needing to be delivered over many years to prevent relapses, it is now time to start exploiting these time-release technologies in psychopharmacology. ◆
Take-Home Points
◆ Psychotropic drugs can have limited utility in psychiatric practice due to their pharmacokinetic properties.
◆ One such limitation is short halflife requiring multiple daily doses, which often reduces compliance.
Technologies that increase duration of action, ranging from once-daily oral or transdermal administration to a bimonthly depot injection, are now available for an increasing array of psychotropic drugs. Increased duration of action will hopefully lead to enhanced compliance.
◆ Another common limitation is the fact that undesirable side effects are associated with both peak plasma drug concentrations and the rapid rise and fall of these concentrations. Technologies that eliminate the rapid peak-andvalley pattern of drug delivery can significantly improve tolerability and make a medication with enhanced therapeutic actions available to a much wider population of patients. 
